Diabetes Care, Vol 18, Issue 6 843-851, Copyright © 1995 by American Diabetes Association

ARTICLES

Safety and efficacy of normalizing fasting glucose with bedtime NPH insulin alone in NIDDM

K Cusi, GR Cunningham and JP Comstock
Medical Service, Department of Veterans Affairs Medical Center, Houston, TX 77030-4298, USA.

OBJECTIVE--To examine the safety and overall clinical effects of normalizing the fasting plasma glucose (FPG) level with bedtime NPH insulin alone in patients with non-insulin-dependent diabetes mellitus (NIDDM) that is poorly controlled with maximal doses of sulfonylureas. RESEARCH DESIGN AND METHODS--Twelve obese male NIDDM subjects were treated for 16 weeks with bedtime insulin after a 4-week sulfonylurea washout. The insulin dosage was increased until the FPG level was normalized. The 24-h plasma glucose profiles and lipid and HbA1c levels were measured at the beginning and end of the study, and the incidence and severity of hypoglycemic episodes were closely monitored. In addition, hyperglycemic clamp studies were performed to assess insulin secretion and provide an indirect measurement of insulin sensitivity. RESULTS--FPG (14.6 +/- 0.9 mmol/l at week 0) was normalized ( < 6.4 mmol/l) within 6 weeks (5.9 +/- 0.6 mmol/l) and remained at target levels until the end of the study (4.0 +/- 0.03 mmol/l at week 16, P < 0.001). The insulin dose was 80 +/- 9 U/day (0.86 +/- 0.10 U/kg). Improved glycemic control was confirmed by a reduction in HbA1c (10.9 +/- 0.05 vs. 7.2 +/- 0.2%, P < 0.001) and mean 24-h glucose (17.2 +/- 0.2 vs. 7.4 +/- 0.2 mmol/l, P < 0.001). The incidence of mild or moderate hypoglycemic episodes was 3.4 +/- 1/patient for the entire 16-week study, and no patient experienced severe hypoglycemia. Bedtime insulin significantly improved total cholesterol, low-density lipoprotein cholesterol, very-low-density lipoprotein cholesterol, and triglyceride levels (P < 0.01). Weight gain was 2.4 +/- 0.7 kg, and blood pressure was unchanged. During the hyperglycemic clamp, there was an improvement in the first phase (P < 0.001) and in the second phase (P < 0.01) of insulin secretion. There also was an increase in the rate of exogenous glucose infused (M) (P < 0.01) and in the M/C-peptide ratio (P < 0.02), suggesting enhanced insulin sensitivity. CONCLUSIONS--NPH insulin given at bedtime in amounts sufficient to achieve a normal FPG level does not cause excessive or severe hypoglycemia and does lead to good glycemic and lipid control in NIDDM. Bedtime insulin therapy also is accompanied by improved insulin secretion and insulin sensitivity. We conclude that a single dose of insulin alone at bedtime merits consideration as a therapeutic strategy in patients with poorly controlled NIDDM.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Massi-Benedetti and M. Orsini-Federici Treatment of Type 2 Diabetes With Combined Therapy: What are the pros and cons? Diabetes Care, February 1, 2008; 31(Supplement_2): S131 - S135. [Abstract] [Full Text] [PDF]

				Z. T. Bloomgarden Exploring Treatment Strategies for Type 2 Diabetes Diabetes Care, October 1, 2007; 30(10): 2737 - 2745. [Full Text] [PDF]

				C. W. Spellman Insulin Therapy for Maximal Glycemic Control in Type 2 Diabetes Mellitus J Am Osteopath Assoc, July 1, 2007; 107(7): 260 - 269. [Abstract] [Full Text] [PDF]

				L. Juurinen, M. Tiikkainen, A.-M. Hakkinen, A. Hakkarainen, and H. Yki-Jarvinen Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E829 - E835. [Abstract] [Full Text] [PDF]

				J. Rosenstock, D. Sugimoto, P. Strange, J. A. Stewart, E. Soltes-Rak, G. Dailey, and on behalf of the Insulin Glargine 4014 Study Inves Triple Therapy in Type 2 Diabetes: Insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care, March 1, 2006; 29(3): 554 - 559. [Abstract] [Full Text] [PDF]

				R. G. Bretzel, S. Arnolds, J. Medding, and T. Linn A Direct Efficacy and Safety Comparison of Insulin Aspart, Human Soluble Insulin, and Human Premix Insulin (70/30) in Patients With Type 2 Diabetes Diabetes Care, May 1, 2004; 27(5): 1023 - 1027. [Abstract] [Full Text] [PDF]

				D. M. Nathan Initial Management of Glycemia in Type 2 Diabetes Mellitus N. Engl. J. Med., October 24, 2002; 347(17): 1342 - 1349. [Full Text] [PDF]

				I. M. El-Kebbi, D. C. Ziemer, C. B. Cook, C. D. Miller, D. L. Gallina, and L. S. Phillips Comorbidity and Glycemic Control in Patients With Type 2 Diabetes Arch Intern Med, May 28, 2001; 161(10): 1295 - 1300. [Abstract] [Full Text] [PDF]

				D. M. Nathan Inhaled Insulin for Type 2 Diabetes: Solution or Distraction? Ann Intern Med, February 6, 2001; 134(3): 242 - 244. [Full Text] [PDF]

				R. C. Turner, C. A. Cull, V. Frighi, R. R. Holman, and for the UK Prospective Diabetes Study Group Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin in Patients With Type 2 Diabetes Mellitus: Progressive Requirement for Multiple Therapies (UKPDS 49) JAMA, June 2, 1999; 281(21): 2005 - 2012. [Abstract] [Full Text] [PDF]

				N. Emanuele, N. Azad, C. Abraira, W. Henderson, J. Colwell, S. Levin, F. Nuttall, J. Comstock, C. Sawin, C. Silbert, et al. Effect of Intensive Glycemic Control on Fibrinogen, Lipids, and Lipoproteins: Veterans Affairs Cooperative Study in Type II Diabetes Mellitus Arch Intern Med, December 1, 1998; 158(22): 2485 - 2490. [Abstract] [Full Text] [PDF]

				S. D. Wise, M. F. Nielsen, P. E. Cryer, and R. A. Rizza Overnight Normalization of Glucose Concentrations Improves Hepatic But Not Extrahepatic Insulin Action in Subjects with Type 2 Diabetes Mellitus J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2461 - 2469. [Abstract] [Full Text]

				BEDTIME INSULIN ALONE FOR NIDDM Journal Watch (General), June 30, 1995; 1995(630): 4 - 4. [Full Text]